Company Profile
Entrada Therapeutics
Company Overview
Entrada Therapeutics is a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol.
Entrada is comprised of experts and leaders in both biologics development and the rare disease space. In December 2018, Entrada closed a $59 million Series A from 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital.